Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Zenas BioPharma, Inc. ( (ZBIO) ).
On October 7, 2025, Zenas BioPharma entered into a license agreement with InnoCare Pharma, granting Zenas exclusive rights to develop and commercialize several small molecule compounds, including orelabrutinib, a BTK inhibitor for multiple sclerosis. This agreement positions Zenas to potentially transform the treatment landscape for progressive MS, with a Phase 3 trial for orelabrutinib already initiated. The deal also includes a $35 million upfront payment and potential milestone payments, reflecting Zenas’s strategic expansion in the autoimmune treatment market.
The most recent analyst rating on (ZBIO) stock is a Hold with a $22.00 price target. To see the full list of analyst forecasts on Zenas BioPharma, Inc. stock, see the ZBIO Stock Forecast page.
Spark’s Take on ZBIO Stock
According to Spark, TipRanks’ AI Analyst, ZBIO is a Neutral.
The overall score is primarily impacted by the company’s poor financial performance, with significant revenue decline and cash flow issues. Technical analysis provides some positive momentum, but the negative valuation metrics further weigh down the score.
To see Spark’s full report on ZBIO stock, click here.
More about Zenas BioPharma, Inc.
Zenas BioPharma, Inc. operates in the biopharmaceutical industry, focusing on the development and commercialization of treatments for autoimmune diseases. The company is advancing a pipeline that includes obexelimab, orelabrutinib, ZB021, and ZB022, targeting immunology and inflammation diseases.
Average Trading Volume: 212,631
Technical Sentiment Signal: Strong Buy
Current Market Cap: $969.8M
For detailed information about ZBIO stock, go to TipRanks’ Stock Analysis page.